Mutations in eight genes (EGFR, ALK, ROS1, NTRK1, NTRK2, NTRK3, MET, RET) are FDA-approved biomarkers predicting response to NSCLC TKIs (Figure 3B). This evidence concerns the gene NTRK2 and non-small cell lung carcinoma.